Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age

Abstract

BACKGROUND Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. METHODS African children vaccinated at 12-23 months of age with PsA-TT were followed… (More)
DOI: 10.1093/cid/civ672

Topics

1 Figure or Table

Cite this paper

@inproceedings{Tapia2015AntibodyP1, title={Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age}, author={Milagritos D. Tapia and Helen Findlow and Olubukola T. Idoko and M P Pr{\'e}ziosi and Prasad Suryakant Kulkarni and Godwin C. Enwere and Cheryl M. Elie and Varsha Parulekar and Samba Ousmane Sow and Fadima Cheick Haidara and Fatoumata Diallo and Moussa F Doumbia and Adebayo Kolawole Akinsola and Richard A. Adegbola and Beate Kampmann and Julie Chaumont and Lionel Martellet and Elisa Marchetti and Simonetta Viviani and Yuxiao Tang and Brian D. Plikaytis and F. Marc LaForce and George M. Carlone and Ray Borrow}, booktitle={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America}, year={2015} }